参与癌症治疗光动力学疗法的反应性减少物种
1MOE Key Laboratory of High Performance Polymer Materials and Technology, Department of Polymer Science and Engineering, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, Jiangsu, 210023, P. R. China.
Chemistry (Weinheim an der Bergstrasse, Germany)
|September 26, 2023
概括
降低光动力学疗法 (R-PDT) 为癌症治疗提供了氧化PDT的有希望的替代方案. 这种不依赖氧气的方法有效地对抗瘤缺氧,并提高治疗结果.
科学领域:
- 生物医学工程 生物医学工程
- 摄影化学的使用.
- 癌症治疗 癌症治疗
背景情况:
- 氧化光动力学疗法 (O-PDT) 在癌症治疗中表现有前途,但面临诸如瘤缺氧和细胞抗氧化防御等挑战.
- 基于活性氧物种 (ROS) 的O-PDT疗效在低氧瘤微环境中是有限的.
研究的目的:
- 引入减少光动力学疗法 (R-PDT) 作为一种新的癌症治疗策略.
- 突出R-PDT的无氧机制和克服O-PDT局限性的潜力.
- 讨论加强R-PDT中的I型光敏化通路的策略.
主要方法:
- 专注于利用基 (H⋅) 生成的R-PDT的最新进展.
- 在R-PDT中探索单个电子转移 (SET) 过程.
- 对提高I型光敏感通道的策略的审查.
主要成果:
- R-PDT显示出显著的疗效,特别是在缺氧或无氧瘤条件下.
- R-PDT的无氧性质绕过了与O-PDT相关的局限性.
- 基和SET过程是近期R-PDT发展的关键机制.
结论:
- R-PDT代表了癌症治疗光动力学疗法的重大进展.
- 它的氧气独立机制使其在挑战瘤微环境方面非常有效.
- 进一步研究R-PDT,特别是H⋅和SET通路,具有很大的治疗潜力.
相关概念视频
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Electron Transport Chain: Complex I and II
14.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


